These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31618089)

  • 1. Ibrutinib-Associated Reversible Cardiomyopathy.
    Liang SH; Chiu CF; Bai LY
    J Oncol Pract; 2019 Dec; 15(12):671-673. PubMed ID: 31618089
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
    Furtado M; Wang ML; Munneke B; McGreivy J; Beaupre DM; Rule S
    Br J Haematol; 2015 Jul; 170(1):131-4. PubMed ID: 25559624
    [No Abstract]   [Full Text] [Related]  

  • 3. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 4. The Muddied Waters of Ibrutinib Therapy.
    Schamroth Pravda M; Schamroth Pravda N; Lishner M
    Acta Haematol; 2019; 141(4):209-213. PubMed ID: 30943468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
    Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
    Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Tobinai K; Uchida T; Fukuhara N; Nishikawa T
    Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
    [No Abstract]   [Full Text] [Related]  

  • 7. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
    Ruella M; Soubeyran P
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
    Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    Jiang H; Lwin T; Zhao X; Ren Y; Li G; Moscinski L; Shah B; Tao J
    Br J Haematol; 2019 Jan; 184(2):298-302. PubMed ID: 29383700
    [No Abstract]   [Full Text] [Related]  

  • 10. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
    Styskel BA; Lopez-Mattei J; Jimenez CA; Stewart J; Hagemeister FB; Faiz SA
    Am J Respir Crit Care Med; 2019 Jun; 199(12):e43-e44. PubMed ID: 30802411
    [No Abstract]   [Full Text] [Related]  

  • 12. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
    Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
    [No Abstract]   [Full Text] [Related]  

  • 13. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    Srour SA; Lee HJ; Nomie K; Ye H; Chen W; Oriabure O; Romaguera J; Wang ML
    Br J Haematol; 2018 May; 181(4):561-564. PubMed ID: 28369820
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
    Kaur V; Swami A
    J Oncol Pharm Pract; 2017 Apr; 23(3):235-239. PubMed ID: 26970573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
    Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
    Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
    Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.